Logotype for Oklo Inc

Oklo (OKLO) Q2 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Oklo Inc

Q2 2026 earnings summary

11 Aug, 2026

Executive summary

  • Achieved first criticality at the Groves isotope facility in under a year, setting a record for privately funded, full-scale nuclear deployment.

  • Advanced Aurora-INL, Ohio clean energy campus, and Eielson Air Force Base projects, with key regulatory milestones and customer agreements secured.

  • Strengthened vertical integration across power, fuel, and isotopes, supported by acquisitions of ARMEC and Creative Engineers, Inc.

  • Expanded manufacturing, engineering, and sodium systems expertise through acquisitions and partnerships.

  • Demonstrated execution capabilities, reducing future project risk and enabling repeatable, scalable deployment.

Financial highlights

  • Year-to-date net loss for Q2 2026 was $81.6 million, with a loss from operations of $124.2 million, offset by $44.5 million in net interest and dividend income.

  • Cash used in operating activities was $65.5 million; investing activities used $912.7 million, including $743.6 million for marketable securities and $126.9 million for property, plant, and equipment.

  • Ended Q2 with $3.0 billion in cash and marketable securities, including $1.9 billion raised via ATM programs in 2026.

  • Revenue for Q2 2026 was $1.2 million, primarily from recent acquisitions.

  • Net loss per share for the six months ended June 30, 2026: $(0.47); weighted-average shares outstanding: 173.3–176.2 million.

Outlook and guidance

  • Capital spending expected to be weighted toward the second half of 2026, with increased visibility into procurement, construction, fuel, and project payment milestones.

  • Aurora-INL remains on track for 2028 startup, with proactive capital deployment to secure long-lead items and ensure project delivery.

  • First isotope revenue anticipated from the Idaho Radiochemistry Lab in early 2027, with Groves ramping up R&D production over the next year.

  • 2026 cash use guidance: $120–$150 million for operating activities and $400–$500 million for capital expenditures.

  • Management believes current liquidity is sufficient for at least the next year.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more